



The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis

Ning Su, Changming Wen, Shiqian Guo, Yang Yu and Chenglin Wang*

Department of Neurology, Nanyang Central Hospital, Nanyang, China

Objective: To explore the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) for motor recovery in non-depressed patients after acute stroke.

Methods: According to the predefined retrieval strategy, multiple electronic databases were searched for randomized controlled trials (RCTs) that met the inclusion criteria. The primary efficacy outcome was measured by Fugl-Meyer Motor Scale (FMMS) score and the indicators of tolerability included withdrawal rate and the incidence of adverse events (AEs).

OPEN ACCESS

Edited by:

Raimund Helbok, Innsbruck Medical University, Austria

Reviewed by:

Miao Chen, University of Shanghai for Science and Technology, China Nikoloz Tsiskaridze, Pineo Medical Ecosystem, Georgia

> *Correspondence: Chenglin Wang chenglinzz@163.com

Specialty section:

This article was submitted to Stroke, a section of the journal Frontiers in Neurology

Received: 03 August 2021 Accepted: 21 September 2021 Published: 20 October 2021

Citation:

Su N, Wen C, Guo S, Yu Y and Wang C (2021) The Efficacy and Tolerability of Selective Serotonin Reuptake Inhibitors for Motor Recovery in Non-depressed Patients After Acute Stroke: A Meta-Analysis. Front. Neurol. 12:749322. doi: 10.3389/fneur.2021.749322 **Results:** 10RCTs were included, the pooled analyses showed patients who received fluoxetine (endpoint: MD = 21.17, 95% Cl 14.13–28.21, P < 0.00001; mean change: MD = 16.27, 95% Cl 10.05–22.50, P < 0.00001) and citalopram (endpoint: MD = 22.93, 95% Cl 11.13–34.73, P = 0.0001; mean change: MD = 24.06, 95% Cl 10.47–37.65, P = 0.0005) experienced greater improvement in FMMS score. There was no evident difference in total withdrawal rate (fluoxetine: OR = 1.11, 95% Cl 0.90–1.27, P = 1.38; citalopram: OR = 0.94, 95% Cl 0.69–1.28, P = 0.71; escitalopram: OR = 0.87, 95% Cl 0.58–1.28, P = 0.47) between two groups. Besides, the incidence of hyponatremia (OR = 2.01, 95% Cl 1.16–3.50, P = 0.01), seizure (OR = 1.46, 95% Cl 1.03–2.08, P = 0.04) and fracture (OR = 2.34, 95% Cl 1.61–3.40, P < 0.00001) in the fluoxetine group was higher than in the placebo group.

Conclusions: Fluoxetine and citalopram can promote motor recovery in non-depressed patients with acute stroke, but it is necessary to pay attention to the possible AEs of fluoxetine, such as hyponatremia, seizure and fracture.

Systematic Review Registration: PROSPERO, identifier [CRD42021227452].

Keywords: efficacy, tolerability, selective serotonin reuptake inhibitors, stroke, meta-analysis

INTRODUCTION

Stroke is the second leading cause of death in the world and a leading cause of long-term functional disability (1). Stroke affects 13.7 million people each year, and approximately half of all survivors are left with a disability (2, 3). In recent years, although great progress has been made in the treatment of acute stroke, post-stroke disability is still an urgent problem to be solved.

1

Many clinical studies have suggested that selective serotonin reuptake inhibitors (SSRIs) might improve functional outcomes after stroke, even in non-depressed patients, through a range of mechanisms, which include enhancing neuroplasticity and promoting neurogenesis (4–6). The previous systematic review (7) has shown that SSRIs seem to reduce disability, dependence, and neurological impairment after stroke. Based on the results of this systematic review (7), three large randomized controlled trials (RCTs) (5, 6, 8) have been designed. However, the FOCUS trial does not demonstrate any benefit on the functional outcome of fluoxetine compared with placebo at 6 months. A subsequent systematic review (9) was conducted based on the previous work, which only included the trials at low risk of bias and the FOCUS, and the results indicated that SSRIs did not improve recovery from stroke.

Given this situation, and two other large studies that have been published, we intend to conduct a meta-analysis and systematically review the relevant literature to evaluate the efficacy and tolerability of SSRIs for motor recovery in nondepressed patients after acute stroke to provide evidence for clinical treatment.

METHODS

The following work was conducted according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement (10). The PROSPERO registration number is CRD42021227452.

Criteria for Considering Studies for This Review

The inclusion criteria were as follows: (1) participants: patients aged 18 years or older with acute post-stroke hemiparesis or hemiplegia and Fugl-Meyer motor scale (FMMS) scores \leq 55 or the mRS score \geq 1; (2) intervention: one of the SSRIs was used as monotherapy, and there was no limit on the dosage and dosage form of them; (3) comparison: placebo; (4) outcome measures: indicators that could reflect efficacy or tolerability. As long as one of these indicators was present in the study, it was considered appropriate; (5) study types: RCTs.

Studies were excluded if they included patients with: (1) depression; (2) severe physical disease; (3) poor response or contraindications to SSRIs previously; (4) severe post-stroke disability or premorbid disabilities including aphasia, cognitive disorders, and motor disorders. Moreover, duplicate publications and studies without available data would also be ruled out.

Search Methods for Identification of Studies

PubMed, Web of Science, Embase, Cochrane Central Register of Controlled Trials, ScienceDirect and Scopus were searched from their inception to November 6, 2020. Only articles published in English would be included. The search terms were: (stroke OR "cerebrovascular accident" OR "cerebral infarction" OR "brain infarction" OR "cerebral hemorrhage" OR "intracranial hemorrhages") AND ("serotonin uptake inhibitors" OR citalopram OR escitalopram OR fluoxetine OR paroxetine OR sertraline OR fluvoxamine). We used a combination of Medical Subject Headings (MESH) words and free words for retrieval, and made corresponding adjustments according to the characteristics of each database. We also searched Clinical Trials.gov to seek the unpublished studies. Details of the search strategy were provided in **Supplementary File 1**. In order not to omit relevant studies, we would also manually retrieve all references of the included literature, as well as those in the systematic reviews and meta-analyses related to the research topic. Finally, we searched again on June 22, 2021, to avoid missing new literature published after the end of our search.

Data Collection and Analysis Selection of Studies

After removing the duplicate literature, two researchers removed the studies that did not meet the inclusion criteria by reading the titles and abstracts of them, and then read the full text of the remaining studies in detail to decide whether they could be included in our study. If there was any disagreement, they should consult with the third researcher to make a decision finally.

Data Extraction and Management

These data were summarized in an Excel spreadsheet: the first authors, publication year, study design, numbers/gender/age of the participants, stroke type, intervention and control measures, duration of treatment, indicators of efficacy and tolerability. Two researchers performed this work independently and a third people helped them solve any controversy that may arise.

Assessment of Risk of Bias in Included Studies

We evaluated the quality of the included RCTs based on the Cochrane Collaboration's tool (11), which mainly involved the following six items: selection bias (random sequence generation and allocation concealment), performance bias (blinding of participants and personnel), detection bias (blinding of outcome assessment), attrition bias (incomplete outcome data), reporting bias (selective reporting), and other biases. The risk of bias for each project is expressed as "low risk," "high risk" or "unclear risk." Among them, "high risk of bias," if present, is unlikely to alter the results seriously, "unclear risk of bias" means it would raise some doubt about the results (11). Two authors evaluated the risk of bias on their own, if there was a disagreement, they could discuss it with a third person.

Measures of Treatment Effect

FMMS is a well-designed, feasible, and efficient clinical examination method that is widely used for assessment of motor recovery after stroke and has excellent intra-rater and inter-rater reliability and validity (12). Thus, the primary efficacy outcome was measured by FMMS score as well as the secondary efficacy outcomes included Barthel Index (BI) score, National Institutes

of Health Stroke Scale (NIHSS) score, modified Rankin Scale (mRS) score, and the proportion of patients with a mRS score of 0–2. Besides, the indicators of tolerability included withdrawal rate and the incidence of adverse events (AEs).

Unit of Analysis Issues

Only randomized, placebo-controlled, parallel-group trials would be included. When trials had diverse treatment arms with different doses or different types of antidepressants, we would compare them with placebo, respectively.

Dealing With Missing Data


For the missing data, we would first try to contact the original authors to get the corresponding data, if not, for dichotomous variables, if there was a lack of one of the number of events or the total number of events in the literature, and the incidence of events was provided, the missing data could be improved by simple conversion. For continuous variables, if the mean and standard deviation (SD) were not provided but only the median and Interquartile Range (IQR) were mentioned in the literature, we would estimate according to the methods mentioned in the studies (13, 14).

Assessment of Heterogeneity

The *P*-value of the chi-square test and I-square (I^2) were used to assess heterogeneity. Low, moderate, and high heterogeneity were defined as I^2 values of 25, 50, and 75%, respectively (15). As for this study, heterogeneity was acceptable as long as I^2 is not >50%. P = 0.10 was set as the threshold for statistical significance (16).

Assessment of Reporting Biases

Our meta-analysis mainly involved publication bias and selective outcome reporting bias. If we had at least 10 studies in the meta-analysis, we would use a funnel plot to qualitatively analyze publication bias, besides, the Begg's and Egger's test would be exploited for potential publication bias assessment quantificationally, and *P*-value < 0.05 would be interpreted as statistically significant (17). To examine the presence of selective outcome reporting bias, we compared the specified outcomes in the trial registry, if they were available, with those reported



References	Case (I/C)	Gender (M/F)	Age (I/C) (years)	Stroke type	Intervention/ control	Dose (mg/d)	Durance	Outcome	Multicenter	Study design
Asadollahi et al. (20)	60 (30/30)	33/27	60.2 ± 8.52/61.7 ± 9.6	Ischemic stroke	Fluoxetine/placebo	20	90d	(1), (6), (7)	Ν	RCT
Asadollahi et al. (20)	60 (30/30)	35/25	58.7 ± 8.56/61.7 ± 9.6	Ischemic stroke	Citalopram/placebo	20	90d	(1), (6), (7)	Ν	RCT
Chollet et al. (4)	118 (59/59)	72/46	$66.4 \pm 11.7/62.9 \pm 13.4$	Ischemic stroke	Fluoxetine/placebo	20	90d	(1), (3), (5), (6), (7)	Υ	RCT
FOCUS Trial Collaboration (5)	3,127 (1,564/1,563)	1,922/1,205	71.2 ± 12.4/71.5 ± 12.1	Intracerebral hemorrhage or ischaemic stroke	Fluoxetine/placebo	20	6 months	(5), (6), (7)	Y	RCT
Kraglund et al. (21)	642 (319/323)	421/221	$68 \pm 13/68 \pm 13$	Ischemic stroke	Citalopram/placebo	20	6 months	(4), (5), (6), (7)	Υ	RCT
Affinity Trial Collaboration (6)	1,280 (642/638)	804/476	63.5 ± 12.5/64.6 ± 12.2	Intracerebral hemorrhage or ischaemic stroke	Fluoxetine/placebo	20	6 months	(5), (6), (7)	Y	RCT
Kim et al. (22)	478 (241/237)	-	-	Intracerebral hemorrhage or ischaemic stroke	Escitalopram/placeb	o 10	12 weeks	(2), (3), (4), (6), (7)	Y	RCT
Effects Trial Collaboration (8)	1,500 (750/750)	925/575	70.6 ± 11.3/71.0 ± 10.5	Intracerebral hemorrhage or ischaemic stroke	Fluoxetine/placebo	20	6 months	(3), (5), (6), (7)	Y	RCT
Marquez-Romero et al. (23)	32 (15/17)	15/15	-	Intracerebral hemorrhage	Fluoxetine/placebo	20	90d	(1), (2), (3), (5), (6), (7)	Y	RCT
Savadi Oskouie et al. (24)	144 (72/72)	-	-	Ischemic stroke	Citalopram/placebo	20	90d	(5), (6), (7)	Ν	RCT

RCTs, randomized controlled trials; I/C, intervention/control; M, male; F, female; Y, yes; N, no; (1) Fugl-Meyer Motor Scale (FMMS) score; (2) Barthel Index (BI) score; (3) National Institutes of Health Stroke Scale (NIHSS) score; (4) modified Rankin Scale (mRS) score; (5) the proportion of patients with a mRS score of 0–2; (6) total withdrawal rate; (7) the incidence of adverse events (AEs).

in the published studies. If not, we would scrutinize the aims and methods of the studies and comparing these with outcomes reported. We determined that if published reports included all prespecified outcomes, then those studies had a low risk of bias.

Data Synthesis

The RevMan 5.3 software from the Cochrane Collaboration was applied for the data synthesis. We pooled mean difference (MD) for continuous data using Inverse Variance methods and odds ratios (OR) for dichotomous data using Mantel-Haenszel methods, reporting pooled results along with their associated 95% confidence intervals (CI). If the P < 0.10 or $I^2 \geq 50\%$, substantial heterogeneity between studies was indicated, and the random-effects model was used;


otherwise, we used the fixed-effect model (18). A *P*-value < 0.05 in the overall effect *Z* test was considered statistically significant (19).

Subgroup Analysis and Investigation of Heterogeneity

Subgroup analysis was often used to deal with heterogeneity. When significant heterogeneity ($I^2 > 50\%$) was found in this study, in addition to using the random-effects model, if the number of studies was sufficient, we could conduct subgroup analysis to explore the source of heterogeneity based on the types of antidepressants.

Sensitivity Analysis

In order to evaluate the robustness of the final results and explore the contribution of each included trial, we would conduct the



sensitivity analysis. Stata 15.1 software was used to recalculate the data after removing the study item by item and observe whether the final statistical results changed or not. Finally, the sensitivity analysis chart was drawn.

RESULTS

Description of Studies

Results of the Search

The literature search identified a total of 1,344 records from electronic databases and the reference lists of retrieved studies, relevant systematic reviews, and meta-analyses.

We used EndNote X9 software to remove duplicate records and carry out manual re-inspection, the 409 duplicate records were removed. We scanned the titles and abstracts of the remaining 935 documents, 911 records that did not meet the inclusion criteria were removed. Then the full-text of 24 articles were carefully evaluated for their eligibility, 15 articles were excluded and 9 studies were included for qualitative synthesis, in addition, 10 RCTs were included in our meta-analysis finally. See **Figure 1** for PRISMA flow diagram.

Included Studies

The main characteristics of the included studies were shown in **Table 1**. All included studies were randomized, double-blind, placebo-controlled trials. These studies were published between 2011 and 2020. The sample size ranged from 32 to 3,127. There were 3,722 participants in the experimental group and 3,689 participants in the control group. Mean age ranged from 58.7 to 71.5 years. The experimental groups of the 10 RCTs were, respectively, 20 mg fluoxetine in 6 RCTs, 20 mg citalopram in 3 RCTs, and 10 mg escitalopram in 1RCT. The course of treatment ranged from 12 weeks to 6 months.

Excluded Studies

We excluded 15 articles for the following reasons: (1) were nonrandomized controlled trials (n = 3), (2) no placebo in control arm (n = 2), (3) depressed patients were enrolled (n = 1),

Α		0001							
Churches and Curle amount		SSRI	Tatal		Control		Mainh 6	Mean Difference	Mean Difference
Study or Subgroup 1.1.1 fluoxetine	Mean	50	Total	wean	20	Total	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% Cl
Asadollahi 2018a	FO 40	00.04	20	07.00	10 71	20	07 50/	04 46 140 00 05 001	
Chollet 2011	52.42 53.7	26.24 27.8		35.1	18.71 22	30 56		24.46 [12.93, 35.99]	
Marguez-Romero 2020	53.7 75.5	27.8	57 14	35.1 48.5		56 16		18.60 [9.36, 27.84] 27.00 [-5.80, 59.80]	
Subtotal (95% CI)	75.5	33	101	40.0	56.9	102		21.17 [14.13, 28.21]	▲
Heterogeneity: Chi ² = 0.7	73. df = 2	(P = 0.	69): l² =	= 0%				• • •	
Test for overall effect: Z	,	•	//						
1.1.2 citalopram									
Asadollahi 2018b	50.89	27.17	30	27.96	18.71	30	26.2%	22.93 [11.13, 34.73]	
Subtotal (95% CI)			30			30	26.2%	22.93 [11.13, 34.73]	
Heterogeneity: Not applie									
Test for overall effect: Z :	= 3.81 (P	9 = 0.00	01)						
Total (95% CI)			131			132	100.0%	21.63 [15.59, 27.68]	•
Heterogeneity: Chi ² = 0.7	79, df = 3	(P = 0.	85); l² =	= 0%					
Test for overall effect: Z =	= 7.01 (P	2000	001)						-50 -25 0 25 50
		< 0.00	001)						
Test for subaroup differe			,	1 (P = ().80). I²	= 0%			Favours [control] Favours [SSRI]
Test for subaroup differe			,	1 (P = ().80). I²	= 0%			Favours [control] Favours [SSRI]
	ences: Ch		,).80). I² ontrol	= 0%		Mean Difference	Havours [control] Havours [SSRI]
Test for subaroup differe B	ences: Ch	ii² = 0.0 SRI	,	с	ontrol		Weight		Mean Difference
Test for subaroup differe B	ences: Ch	ii² = 0.0 SRI	6. df =	с	ontrol		Weight		Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine	ences: Ch	i ² = 0.0 SRI SD	6. df =	с	ontrol SD		<u>Weight</u> 18.1%		Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine	ences: Ch S <u>Mean</u>	ni ² = 0.0 SRI SD - 29.99	6. df = <u>Total</u>	C <u>Mean</u>	ontrol SD	Total	-	IV, Fixed, 95% CI	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a	ences: Ch S <u>Mean</u> 32.34 2	ni ² = 0.0 SRI SD - 29.99	6. df = 1 Total 30	C <u>Mean</u> 9.76	ontrol SD 21.92	<u>Total</u> 30	- 18.1% 64.5%	IV, Fixed, 95% CI 22.58 [9.29, 35.87]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011	ences: Ch S <u>Mean</u> 32.34 2 36.4	i ² = 0.0 SRI SD 29.99 21.3	6. df = Total 30 57 87	C <u>Mean</u> 9.76 21.9	ontrol SD 21.92 16.7	<u>Total</u> 30 56	- 18.1% 64.5%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI)	ences: Ch S <u>Mean</u> 32.34 2 36.4 :11, df =	i ² = 0.0 SRI <u>SD</u> 29.99 21.3 1 (P = 0	6. df = <u>Total</u> 30 57 87 0.29); I ²	C <u>Mean</u> 9.76 21.9	ontrol SD 21.92 16.7	<u>Total</u> 30 56	- 18.1% 64.5%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% Cl) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram	ences: Ch S <u>Mean</u> 32.34 2 36.4 :11, df =	i ² = 0.0 SRI <u>SD</u> 29.99 21.3 1 (P = 0	6. df = <u>Total</u> 30 57 87 0.29); I ²	C <u>Mean</u> 9.76 21.9	ontrol SD 21.92 16.7	<u>Total</u> 30 56	- 18.1% 64.5%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram	ences: Ch S <u>Mean</u> 32.34 2 36.4 :11, df =	i ² = 0.0 SRI <u>SD</u> 29.99 21.3 1 (P = 0	6. df = <u>Total</u> 30 57 87 0.29); I ²	C <u>Mean</u> 9.76 21.9 ² = 10%	ontrol SD 21.92 16.7	<u>Total</u> 30 56	18.1% 64.5% 82.6% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% Cl) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram	8 2.34 2 32.34 2 36.4 11, df = 5.12 (l	i ² = 0.0 SRI <u>SD</u> - 29.99 21.3 1 (P = 0 P < 0.00	6. df = <u>Total</u> 30 57 87 0.29); I ² 0001)	C <u>Mean</u> 9.76 21.9 ² = 10%	ontrol SD 21.92 16.7	Total 30 56 86	18.1% 64.5% 82.6% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram Asadollahi 2018b	S Mean 32.34 2 36.4	i ² = 0.0 SRI <u>SD</u> - 29.99 21.3 1 (P = 0 P < 0.00	6. df = Total 1 30 57 87 0.29); I ² 0001) 30	C <u>Mean</u> 9.76 21.9 ² = 10%	ontrol SD 21.92 16.7	Total 30 56 86 30	18.1% 64.5% 82.6% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram Asadollahi 2018b Subtotal (95% CI)	80000000000000000000000000000000000000	i ² = 0.0 SRI 29.99 21.3 1 (P = 0 P < 0.00 31	6. df = Total 30 57 87 0.29); I ² 0001) 30 30 30	C <u>Mean</u> 9.76 21.9 ² = 10%	ontrol SD 21.92 16.7	Total 30 56 86 30	18.1% 64.5% 82.6% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% Cl) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram Asadollahi 2018b Subtotal (95% Cl) Heterogeneity: Not appli	80000000000000000000000000000000000000	i ² = 0.0 SRI 29.99 21.3 1 (P = 0 P < 0.00 31	6. df = Total 30 57 87 0.29); I ² 0001) 30 30 30	C <u>Mean</u> 9.76 21.9 ² = 10%	ontrol SD 21.92 16.7	Total 30 56 86 30 30 30	18.1% 64.5% 82.6% 17.4% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65]	Mean Difference
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram Asadollahi 2018b Subtotal (95% CI) Heterogeneity: Not appli Test for overall effect: Z	S Mean 32.34 2 36.4 11, df = = 5.12 (I 33.82 icable = 3.47 (I	$ii^{2} = 0.0$ SRI 29.99 21.3 1 (P = 0 P < 0.00 31 P = 0.00	6. df = Total 30 57 87 0.29); ² 0001) 30 30 30 005) 117	C 9.76 21.9 2 = 10% 9.76	ontrol SD 21.92 16.7	Total 30 56 86 30 30 30	18.1% 64.5% 82.6% 17.4% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65] 24.06 [10.47, 37.65]	Mean Difference IV, Fixed, 95% CI
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram Asadollahi 2018b Subtotal (95% CI) Heterogeneity: Not appli Test for overall effect: Z Total (95% CI)	S Mean 32.34 36.4 11, df = = 5.12 (l 33.82 icable = 3.47 (l 15, df = 3	$ii^{2} = 0.0$ SRI 29.99 21.3 1 (P = 0 P < 0.00 31 P = 0.00 2 (P = 0	6. df = Total 30 57 87 87 0.29); l ² 0001) 30 30 005) 117 0.34); l ²	C 9.76 21.9 2 = 10% 9.76	ontrol SD 21.92 16.7	Total 30 56 86 30 30 30	18.1% 64.5% 82.6% 17.4% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65] 24.06 [10.47, 37.65]	Mean Difference IV, Fixed, 95% CI
Test for subaroup differe B Study or Subgroup 1.2.1 fluoxetine Asadollahi 2018a Chollet 2011 Subtotal (95% CI) Heterogeneity: Chi ² = 1. Test for overall effect: Z 1.2.2 citalopram Asadollahi 2018b Subtotal (95% CI) Heterogeneity: Not appli Test for overall effect: Z Total (95% CI) Heterogeneity: Chi ² = 2.	S Mean 32.34 36.4 11, df = = 5.12 (I 33.82 icable = 3.47 (I .15, df = : = 6.10 (I	$ii^{2} = 0.0$ SRI SD 29.99 21.3 1 (P = 0 P < 0.00 31 P = 0.00 2 (P = 0 P < 0.00	6. df = Total 30 57 87 0.29); l ² 0001) 30 30 005) 117 0.34); l ² 0001)	C 9.76 21.9 2 = 10% 9.76	ontrol SD 21.92 16.7 21.92	Total 30 56 86 30 30 116	18.1% 64.5% 82.6% 17.4% 17.4%	IV, Fixed, 95% CI 22.58 [9.29, 35.87] 14.50 [7.45, 21.55] 16.27 [10.05, 22.50] 24.06 [10.47, 37.65] 24.06 [10.47, 37.65]	Mean Difference IV, Fixed, 95% CI

A	SSR	1	Contr	ol		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	M-H, Random, 95% Cl
2.1.1 fluoxetine							
Affinity Trial Collaboration 2020	432	642	458	638	21.0%	0.81 [0.64, 1.03]	
Chollet 2011	15	57	5	55	7.2%	3.57 [1.20, 10.64]	
Effects Trial Collaboration 2020	466	750	475	750	21.5%	0.95 [0.77, 1.17]	+
Focus Trial Collaboration 2019	572	1553	588	1553	22.3%	0.96 [0.83, 1.11]	+
Marquez-Romero 2020	8	14	3	16	3.9%	5.78 [1.12, 29.85]	
Subtotal (95% CI)		3016		3012	75.8%	1.00 [0.79, 1.27]	♦
Total events	1493		1529				
Heterogeneity: Tau ² = 0.04; Chi ² = Test for overall effect: Z = 0.00 (P		f = 4 (P	= 0.02);	² = 67%	, D		
2.1.2 citalopram							
Kraglund 2018	231	319	261	323	18.5%	0.62 [0.43, 0.90]	
Oskouie 2017	55	58	22	50	5.7%	23.33 [6.43, 84.70]	
Subtotal (95% CI)		377		373	24.2%	3.62 [0.10, 135.87]	
Total events	286		283				
Heterogeneity: $Tau^2 = 6.61$; $Chi^2 =$ Test for overall effect: Z = 0.70 (P		f = 1 (P	< 0.0000	1); ² =	97%		
Total (95% CI)		3393		3385	100.0%	1.20 [0.85, 1.71]	•
Total events	1779		1812				
Heterogeneity: Tau ² = 0.14; Chi ² =	,	f = 6 (P	< 0.0000	1); I² =	85%	F	0.01 0.1 1 10 100
Test for overall effect: Z = 1.03 (P	,					· · · · ·	Favours [SSRI] Favours [control]
Test for subaroup differences: Chi	i² = 0.48. (df = 1 (i	P = 0.49).	$l^2 = 0\%$	n		
3	SRI		Contro	ı		Mean Difference	Mean Difference
		al Me			Weight	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl
2.2.1 citalopram	00 100	<u>ui 1110</u>		10101	mongine		
terms a second prov	1 5 04	0	10 10	202	CE C0/	0.001.0.01.0.111	
Kraglund 2018 1.5 Subtotal (95% CI)	1.5 31 31		1.3 1.2	323 323		0.20 [-0.01, 0.41] 0.20 [-0.01, 0.41]	
Heterogeneity: Not applicable Test for overall effect: Z = 1.86 (P = 0.06)						
2.2.2 escitalopram							
2.2.2 escitalopram	1 4 9 2 1	10	3 1 4 9	195	34.4%	0 00 [-0 29 0 29]	
Kim 2017 3 ²	1.49 21 21		3 1.49	195 195		0.00 [-0.29, 0.29] 0.00 [-0.29. 0.29]	
A DE LES EL PROPERTIES AND A DE LES ANTES ANTES A DE LES ANTES A D	21	0	3 1.49	195 195		0.00 [-0.29, 0.29] 0.00 [-0.29, 0.29]	
Kim 2017 3 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: Z = 0.00 (21 P = 1.00)	0	3 1.49	195	34.4%	0.00 [-0.29, 0.29]	
Kim 2017 3 Subtotal (95% CI) Heterogeneity: Not applicable	21 P = 1.00) 52 1 (P = 0.2 P = 0.13)	0 29 27); I ² =	- 16%	195 518	34.4% 100.0%		-0.5 0 0.5 1 Favours [SSRI] Favours [control]
Kim 2017 3 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: $Z = 0.00$ (Total (95% CI) Heterogeneity: Chi ² = 1.20, df = Test for overall effect: $Z = 1.51$ (Test for subaroup differences: C	21 P = 1.00) 52 1 (P = 0.2 P = 0.13) hi ² = 1.20	0 29 27); I ² =	: 16% I (P = 0.2	195 518 ?7). ² =	34.4% 100.0%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1	Favours [SSRI] Favours [control]
Kim 2017 3 Subtotal (95% CI) Heterogeneity: Not applicable Test for overall effect: $Z = 0.00$ (Total (95% CI) Heterogeneity: Chi ² = 1.20, df = Test for overall effect: $Z = 1.51$ (Test for subaroup differences: C	21 P = 1.00) 52 1 (P = 0.2 P = 0.13) hi ² = 1.20 SRI	0 29 27); l ² = 0. df = 1	= 16% I (P = 0.2 Contro	195 518 ?7). I ² = I	34.4% 100.0% 16.3%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroup differences: CCStudy or SubgroupMean	21 P = 1.00) 52 1 (P = 0.2 P = 0.13) hi ² = 1.20 SRI	0 29 27); l ² = 0. df = 1	= 16% I (P = 0.2 Contro	195 518 ?7). I ² = I	34.4% 100.0% 16.3%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1	Favours [SSRI] Favours [control]
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroup differences: CStudy or SubgroupMean2.3.1 citalopram	21 P = 1.00) 52 1 (P = 0.2 P = 0.13) $hi^2 = 1.20$ SRI SD Tot	0 29 27); I ² = 0. df = 1 <u>al Me</u> a	= 16% (P = 0.2 Contro SD	195 518 ?7). ² = I 	34.4% 100.0% 16.3% Weight	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% CI	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2	21 P = 1.00) 52 1 (P = 0.2) P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31	0 27); I ² = 0. df = 1 <u>al Me</u> :	= 16% I (P = 0.2 Contro	195 518 27). ² = I <u>Total</u> 323	34.4% 100.0% 16.3% Weight 75.6%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% Cl 0.20 [-0.03, 0.43]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)	21 P = 1.00) 52 1 (P = 0.2 P = 0.13) $hi^2 = 1.20$ SRI SD Tot	0 27); I ² = 0. df = 1 <u>al Me</u> :	= 16% (P = 0.2 Contro SD	195 518 ?7). ² = I 	34.4% 100.0% 16.3% Weight 75.6%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% CI	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)	21 P = 1.00) 52 1 ($P = 0.2$) P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31	0 27); I ² = 0. df = 1 <u>al Me</u> : 9 9	= 16% (P = 0.2 Contro SD	195 518 27). ² = I <u>Total</u> 323	34.4% 100.0% 16.3% Weight 75.6%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% Cl 0.20 [-0.03, 0.43]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicable	21 P = 1.00) 52 1 ($P = 0.2$) P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31	0 27); I ² = 0. df = 1 <u>al Me</u> : 9 9	= 16% (P = 0.2 Contro SD	195 518 27). ² = I <u>Total</u> 323	34.4% 100.0% 16.3% Weight 75.6%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% Cl 0.20 [-0.03, 0.43]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroup differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopram	21 P = 1.00) 52 1 ($P = 0.2$) P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31	0 27); l ² = 0. df = 1 <u>al Me</u> : 19 9	= 16% (P = 0.2 Contro SD	195 518 27). ² = I <u>Total</u> 323 323	34.4% 100.0% 16.3% <u>Weight</u> 75.6% 75.6%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% CI 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroup differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopram	21 P = 1.00) 52 1 (P = 0.2 P = 0.13) hi ² = 1.20 SRI SD Tot 1.66 31 31 P = 0.09)	0 27); ² = 0. df = 1 al Mea 19 9	= 16% I (P = 0.2 Contro an SD 1 1.34	195 518 27). ² = I <u>Total</u> 323 323	34.4% 100.0% 16.3% <u>Weight</u> 75.6% 75.6% 24.4%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% CI 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroup differences: CCStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopramKim 20171Subtotal (95% CI)	21 P = 1.00) 52 1 (P = 0.2) P = 0.13) $h^{2} = 1.20$ SRI SD Tot 1.66 31 31 P = 0.09) 2.11 21	0 27); ² = 0. df = 1 al Mea 19 9	= 16% I (P = 0.2 Contro an SD 1 1.34	195 518 27). ² = I <u>Total</u> 323 323 195	34.4% 100.0% 16.3% <u>Weight</u> 75.6% 75.6% 24.4%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV. Fixed, 95% Cl 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43] 0.00 [-0.41, 0.41]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CCStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopramKim 20171	21 P = 1.00) 52 1 (P = 0.2) P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31 P = 0.09) 2.11 21 21	0 9 277); I ² = 0. df = 1 3 9 9 0 0	= 16% I (P = 0.2 Contro an SD 1 1.34	195 518 27). ² = I <u>Total</u> 323 323 195	34.4% 100.0% 16.3% <u>Weight</u> 75.6% 75.6% 24.4%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV. Fixed, 95% Cl 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43] 0.00 [-0.41, 0.41]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopramKim 20171Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (21 P = 1.00) 52 1 (P = 0.2) P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31 P = 0.09) 2.11 21 21 P = 1.00)	0 27); l ² = 0. df = 1 1 19 9 9	= 16% I (P = 0.2 Contro an SD 1 1.34	195 518 77). ² = 1 <u>Total</u> 323 323 195	34.4% 100.0% 16.3% Weight 75.6% 75.6% 24.4% 24.4%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% Cl 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43] 0.00 [-0.41, 0.41] 0.00 [-0.41, 0.41]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopramKim 20171Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)	21 P = 1.00) 52 P = 0.2 P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31 P = 0.09) 2.11 21 21 P = 1.00) P = 1.00)	0 27); l ² = 0. df = 1 1 19 9 0 0	= 16% I (P = 0.2 Contro an <u>SD</u> 1 1.34 1 2.11	195 518 77). ² = 1 <u>Total</u> 323 323 195	34.4% 100.0% 16.3% Weight 75.6% 75.6% 24.4% 24.4%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV. Fixed, 95% Cl 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43] 0.00 [-0.41, 0.41]	Favours [SSRI] Favours [control] Mean Difference
Kim 20173Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (Total (95% CI)Heterogeneity: Chi ² = 1.20, df =Test for overall effect: $Z = 1.51$ (Test for overall effect: $Z = 1.51$ (Test for subaroub differences: CStudy or SubgroupMean2.3.1 citalopramKraglund 20181.2Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 1.68$ (2.3.2 escitalopramKim 20171Subtotal (95% CI)Heterogeneity: Not applicableTest for overall effect: $Z = 0.00$ (21 P = 1.00) 52 P = 0.2 P = 0.13) $hi^2 = 1.20$ SRI SD Tot 1.66 31 31 P = 0.09) 2.11 21 21 P = 1.00) 52 1 ($P = 0.4$)	0 27); ² = 0. df = 1 10 9 9 10 0 10 0 11); ² =	= 16% I (P = 0.2 Contro an SD 1 1.34 1 2.11	195 518 77). ² = 1 <u>Total</u> 323 323 195	34.4% 100.0% 16.3% Weight 75.6% 75.6% 24.4% 24.4%	0.00 [-0.29, 0.29] 0.13 [-0.04, 0.30] -1 Mean Difference IV, Fixed, 95% Cl 0.20 [-0.03, 0.43] 0.20 [-0.03, 0.43] 0.00 [-0.41, 0.41] 0.00 [-0.41, 0.41]	Favours [SSRI] Favours [control] Mean Difference

FIGURE 4 | Forest plot of secondary efficacy outcomes. (A) The proportion of the number of people with mRS score 0–2, (B) mRS-endpoint score, (C) mRS-mean change. mRS, modified Rankin Scale.

(4) repeated publications (n = 2), (5) unable to obtain valid data (n = 7).

Risk of Bias in Included Studies

Risk of bias assessment of the included studies was presented in **Figure 2** (A: risk of bias graph; B: risk of bias summary).

Effects of Interventions

Primary Efficacy Outcomes

FMMS-Endpoint Score

We found evidence showing a benefit for fluoxetine (4, 20, 23) compared to placebo (3RCTs, MD = 21.17, 95% CI 14.13–28.21, P < 0.00001). No heterogeneity was detected (P = 0.69, $I^2 = 0$ %).One study on citalopram (20) showed a benefit for the drug compared to placebo (MD = 22.93, 95% CI 11.13–34.73, P = 0.0001) (Figure 3A).

FMMS-Mean Change

We found evidence showing a benefit for fluoxetine (4, 20) compared to placebo (2RCTs, MD = 16.27, 95% CI 10.05–22.50, P < 0.00001). No heterogeneity was detected (P = 0.29, $I^2 = 10\%$).One study on citalopram (20) showed a benefit for the drug compared to placebo (MD = 24.06, 95% CI 10.47–37.65, P = 0.0005) (Figure 3B).

Secondary Efficacy Outcomes

The Proportion of the Number of People With mRS Score 0-2 There was no significant difference in the proportion of patients with a mRS score of 0-2 at the end of treatment between the fluoxetine (4-6, 8, 21] (5RCTs, OR = 1.00, 95% CI 0.79-1.27, P = 1.00) and citalopram groups (21, 24) (2RCTs, OR = 3.62, 95% CI 0.10-135.87, P = 0.49) compared to the placebo group. The heterogeneity of the two groups was significant (fluoxetine: P = 0.02, $I^2 = 67\%$; citalopram: P < 0.00001, $I^2 = 97\%$), so the random-effects model was applied (**Figure 4A**).

mRS-Endpoint Score

A total of two studies reported relevant data, namely citalopram (21) (MD = 0.20, 95% CI -0.01 to 0.41, P = 0.06) and escitalopram (22) (MD = 0.00, 95% CI -0.29 to 0.29, P = 1.00) in the treatment group, and the results showed no statistical difference compared with the control group (**Figure 4B**).

mRS-Mean Change

There was no significant difference in the mean change of mRS between citalopram (21) (MD = 0.20, 95% CI -0.03 to 0.43, P = 0.09) and escitalopram (22) (MD = 0.00, 95% CI -0.41 to 0.41, P = 1.00) groups at the end of treatment compared with the control group (**Figure 4C**).

NIHSS-Endpoint Score

There was no statistically significant difference in NIHSS score at the end of treatment between fluoxetine (4, 8, 23) (3RCTs, MD = -0.01, 95% CI -0.17 to 0.14, P = 0.86) and placebo. No significant heterogeneity was found (P = 0.18, $I^2 = 41\%$). One study found no significant difference between

escitalopram (22) (MD = 0.10, 95% CI -0.41 to 0.61, P = 0.70) and placebo (**Figure 5A**).

NIHSS-Mean Change

There was no evidence that fluoxetine (4) (MD = 0.80, 95% CI -1.34 to 2.94, P = 0.46) and escitalopram (22) (MD = 0.20, 95% CI -0.56 to 0.96, P = 0.61) changed NIHSS score significantly at the end of treatment compared to the control group (**Figure 5B**).

BI-Endpoint Score

A total of two studies reported relevant data, namely fluoxetine (23) (MD = 20.00, 95% CI -17.58 to 57.58, P = 0.30) and escitalopram (22) (MD = -2.00, 95% CI -6.81 to 2.81, P = 0.42) in the treatment group, and the results showed no statistical difference compared with the control group (**Figure 5C**).

The Tolerability Outcomes

Withdrawal Rate

All RCTs described total withdrawal rate, the results showed that the total withdrawal rate of fluoxetine (6RCTs, OR = 1.11, 95% CI 0.90–1.27, P = 1.38), citalopram (3RCTs, OR = 0.94, 95% CI 0.69–1.28, P = 0.71) and escitalopram (1RCT, OR = 0.87, 95% CI 0.58–1.28, P = 0.47) were not significantly different compared with placebo. No heterogeneity was detected (P = 0.76, $I^2 = 0$ %) (**Figure 6**).

The Incidence of AEs

After the meta-analysis of the AEs reported in the included RCTs, we found that the incidence of hyponatremia (4–6, 8] (OR = 2.01, 95% CI 1.16–3.50, P = 0.01) (**Figure 7A**), seizure (4–6, 8] (OR = 1.46, 95% CI 1.03–2.08, P = 0.04) (**Figure 7B**), and fracture (5, 6, 8, 23] (OR = 2.34, 95% CI 1.61–3.40, P < 0.00001) (**Figure 7C**) in the fluoxetine group was higher than in the placebo group. Other AEs unrelated to SSRIs reported in the included RCTs were shown in **Table 2**.

Publication Bias

The funnel plot was shown in **Figure 8A**. It could be seen that there might be publication bias and the asymmetry was mainly caused by the existence of small sample studies (23), but the quantitative analysis did not support the existence of publication bias (Begg's: P = 0.721, Egger's: P = 0.604). See **Figure 8B** for the Egger test diagram.

Sensitivity Analyses

We conducted sensitivity analyses on the main outcome indicators and the results were all robust (see **Supplementary File 2**).

DISCUSSION

Summary of Main Results

In this meta-analysis, we included 9 trials (10RCTs), including 7,411 participants, 3,722 participants in the experimental group, and 3,689 participants in the control group. In terms of efficacy, the results showed that fluoxetine and citalopram improved the FMMS score better than the placebo. However, there was no significant difference in NIHSS, mRS and BI score between

			SSRI			ontrol			Mean Difference	Mean Difference
Study or Subgroup		Mean	SD	Total	Mean	SD	Total W	leight	IV, Fixed, 95% CI	I IV, Fixed, 95% CI
3.1.1 fluoxetine										
Chollet 2011		5.8		57	6.9				-1.10 [-2.61, 0.41]	
Effects Trial Collaboration	2020	1		678		1.49			0.00 [-0.16, 0.16]	₽
/arquez-Romero 2020 Subtotal (95% Cl)		8.5	3.3	14 749	12	11.4	16 752 9		-3.50 [-9.35, 2.35] -0.01 [-0.17, 0.14]	· •
leterogeneity: Chi ² = 3.39 est for overall effect: Z =			,				102	51.270	-0.01 [-0.11, 0.14]	
.1.2 escitalopram										
(im 2017		2.6	2.9	210	2.5	2.3	195	8.8%	0.10 [-0.41, 0.61]	
Subtotal (95% CI)		2.0	2.0	210	2.0	2.0	195		0.10 [-0.41, 0.61]	
leterogeneity: Not applica	ble									
est for overall effect: Z =		= 0.70)							
otal (95% CI)				959			947 10	nn n%	-0.00 [-0.15, 0.15]	•
leterogeneity: Chi ² = 3.57	df = 3	$(\mathbf{P} = 0)$	31)· l² =				547 10	50.070	-0.00 [-0.13, 0.13]	+ + + +
est for overall effect: Z =		•		1070						-2 -1 0 1 3
est for subaroup difference				1 (P = 0	.67). I²	= 0%				Favours [SSRI] Favours [control]
		SRI	_		Contro	-			an Difference	Mean Difference
	Mean	SD	Total	Mean	SD	Tota	I Weigh	nt IV	/, Fixed, 95% Cl	IV, Fixed, 95% Cl
3.2.1 fluoxetine										
Chollet 2011	7	5.38	57	6.2	6.15				.80 [-1.34, 2.94]	
Subtotal (95% CI)			57			55	5 11.19	% 0.8	80 [-1.34, 2.94]	
Heterogeneity: Not appli	cable									
Test for overall effect: Z	= 0.73	(P = 0	.46)							
3.2.2 escitalopram										
Kim 2017	2.3	4.17	210	2.1	3.62				20 [-0.56, 0.96]	The second secon
Subtotal (95% CI)			210			195	5 88.9	% 0.2	20 [-0.56, 0.96]	
Heterogeneity: Not appli	cable									
Test for overall effect: Z	= 0.52	(P = 0	.61)							
Гotal (95% СІ)			267			250	100.09	% 0 3	27 [-0.45, 0.98]	•
Heterogeneity: Chi ² = 0.1	27 df -	- 1 /D -		· 12 – 0	0/_	100	10010		- [0110, 0100]	
Test for overall effect: Z		•		, 1 – 0	70					-4 -2 0 2 4
Test for subaroup difference. 2			,	lf = 1 (P = 0.6	60). I² =	= 0%			Favours [SSRI] Favours [control]
		0001							Difference	
Study or Subgroup		SSRI SD	Total		Control		Weight		an Difference IV, Fixed, 95% Cl	Mean Difference IV, Fixed, 95% Cl
.1.1 fluoxetine	mean	50	Total	meal	50	1010	meight	·	11, 1 IAGU, 35 /0 OL	14, 1 ACd, 35/0 01
Marquez-Romero 2020	65	21.4	14	45	73.2	16			00 [-17.58, 57.58]	
Subtotal (95% CI)	-1-1-		14			16	1.6%	20.0	0 [-17.58, 57.58]	
Heterogeneity: Not applic Test for overall effect: Z =		P = 0.3	0)							
4.1.2 escitalopram										<u> </u>
Kim 2017	82.6	26.4	210	84.6	23	195	98.4%	-	2.00 [-6.81, 2.81]	
Subtotal (95% CI)			210			195	98.4%		2.00 [-6.81, 2.81]	•
Heterogeneity: Not applic Fest for overall effect: Z =		P = 0.4	2)							
							100.0%		4 6 4 5 6 40 0 401	
			224							
Гotal (95% СІ)	0 46 - 4	L (D – 1	224			211	100.076	, -	1.64 [-6.42, 3.13]	
			0.26); l²	² = 23%	þ	211	100.076	, -	1.04 [-0.42, 3.13] -	-50 -25 0 25 50 Favours [SSRI] Favours [control]

FIGURE 5 | Forest plot of secondary efficacy outcomes. (A) NIHSS-endpoint score, (B) NIHSS-mean change, (C) BI-endpoint score. NIHSS, National Institutes of Health Stroke Scale; BI, Barthel Index.

the two groups. Concerning the tolerability, there was no evident difference in the total withdrawal rate between the two groups. After summarizing and analyzing a variety of AEs reported in the RCTs, we found that the incidence of hyponatremia, seizure, and fracture in the fluoxetine group was higher than that in the placebo group, and there was no statistical

	SSR		Conti			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
5.1.1 fluoxetine							
Affinity Trial Collaboration 2020	30	642	17	638	5.5%	1.79 [0.98, 3.28]	-
Asadollahi 2018a	6	30	5	30	1.4%	1.25 [0.34, 4.64]	
Chollet 2011	2	59	3	59	1.0%	0.65 [0.11, 4.07]	
Effects Trial Collaboration 2020	13	750	8	750	2.7%	1.64 [0.67, 3.97]	
Focus Trial Collaboration 2019	140	1564	140	1563	43.0%	1.00 [0.78, 1.28]	· • • • • • • • • • • • • • • • • • • •
Marquez-Romero 2020	1	15	1	17	0.3%	1.14 [0.07, 20.02]	· · · · · · · · · · · · · · · · · · ·
Subtotal (95% CI)		3060		3057	53.8%	1.11 [0.90, 1.38]	•
Total events	192		174				
Heterogeneity: Chi ² = 4.19, df = 5); $ ^2 = 0$	%				
Test for overall effect: Z = 0.97 (P	= 0.33)						
5.1.2 citalopram							
Asadollahi 2018b	4	30	5	30	1.5%	0.77 [0.19, 3.20]	
Kraglund 2018	97	319	101	323	23.6%	0.96 [0.69, 1.34]	
Oskouie 2017	10	72	11	72	3.2%	0.89 [0.35, 2.26]	
Subtotal (95% CI)		421		425	28.2%	0.94 [0.69, 1.28]	•
Total events	111		117				
Heterogeneity: $Chi^2 = 0.10$, df = 2 Test for overall effect: Z = 0.37 (P	•); l² = 0	%				
5.1.3 escitalopram							
Kim 2017	67	241	73	237	17.9%	0.87 [0.58, 1.28]	
Subtotal (95% CI)		241		237	17.9%	0.87 [0.58, 1.28]	
Total events	67		73				
Heterogeneity: Not applicable							
Test for overall effect: Z = 0.72 (P	= 0.47)						
Total (95% CI)		3722		3719	100.0%	1.02 [0.87, 1.20]	•
Total events	370		364				
Heterogeneity: Chi ² = 5.78, df = 9	(P = 0.76); I² = 0	%				0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z = 0.24 (P	= 0.81)						Favours [SSRI] Favours [control]
Test for subaroup differences: Chi	² = 1.55. (df = 2 (I	P = 0.46)	l² = 0%	6		
FIGURE 6 Forest plot of total withdraw	val rate.						

difference in the incidence of other reported AEs between the two groups.

Overall Completeness and Applicability of Evidence

In electronic database retrieval, according to our relatively broad search strategy, we could obtain as much literature as possible about SSRIs and stroke, to avoid missing eligible literature as far as possible. On this basis, we then screened the trials that met our inclusion criteria. We also searched unpublished studies and references that may meet the inclusion criteria, Besides, all the RCTs included fully reported predetermined results and provided detailed data for analysis. Thus, the comprehensiveness of our meta-analysis could be realized.

The trials included in the meta-analysis are all double-blind, placebo-controlled RCTs, and a total of 7,411 participants are included in the analysis. The sample size is large enough, and patients with ischemic and hemorrhagic stroke are also included in the study. Therefore, we believe that the basic characteristics of patients can represent the current situation of patients in the real world, so we consider that the results of the meta-analysis are applicable to clinical practice. However, most of the RCTs exclude patients with cognitive impairment, aphasia, and severe strokes that could be life-threatening, which may be a negative factor affecting the applicability of evidence, as such patients also account for a certain proportion in actual clinical practice. Patients enrolled in all RCTs have different time requirements from the onset, but the maximum time is within 3 weeks of onset, and since only fluoxetine, citalopram, and escitalopram are involved in the study, we can not provide evidence on the efficacy and tolerability of SSRIs beyond 3 weeks or other SSRIs.

Quality of the Evidence

We have evaluated the study based on the information provided in the RCTs, and the overall risk of bias is low. Among them, the baseline data provided by Kim et al. and Savadi Oskouie et al. (22, 24) is not the actual baseline values, so attrition bias and other bias may exist. In addition, a few RCTs do not report in detail the allocation concealment and blind method, making it difficult to determine the risk of bias. However, in the final pooled analysis of the main results, the heterogeneity is low, indicating that the

	fluoxet	ine	placel	00		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Affinity Trial Collaboration 2020	3	642	2	638	10.7%	1.49 [0.25, 8.96]	
Chollet 2011	2	57	2	56	10.4%	0.98 [0.13, 7.22]	
Effects Trial Collaboration 2020	11	750	1	750	5.3%	11.15 [1.44, 86.57]	
Focus Trial Collaboration 2019	22	1564	14	1563	73.7%	1.58 [0.80, 3.10]	+
Total (95% CI)		3013		3007	100.0%	2.01 [1.16, 3.50]	◆
Total events	38		19				
Heterogeneity: Chi ² = 3.78, df = 3	(P = 0.29)); I ² = 2	1%			H	0.01 0.1 1 10 100
Test for overall effect: Z = 2.47 (P	= 0.01)					C	Favours [fluoxetine] Favours [control]
	fluoxet	ine	placel	00		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total			Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Affinity Trial Collaboration 2020	10	642	2	638	3.8%	5.03 [1.10, 23.06]	
Chollet 2011	1	57	0	56	0.9%	3.00 [0.12, 75.22]	
Effects Trial Collaboration 2020	8	750	11	750	21.0%	0.72 [0.29, 1.81]	
Focus Trial Collaboration 2019	58	1564	40	1563	74.3%	1.47 [0.97, 2.21]	⊢ ∎−
Total (95% CI)		3013		3007	100.0%	1.46 [1.03, 2.08]	•
Total events	77		53				
Heterogeneity: $Chi^2 = 4.98$, df = 3		$1^2 = 4$				-	+ + + + + + +
	(, , , , , , , , , , , , , , , , , , ,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0 /0				0.1 0.2 0.5 1 2 5 10
Test for overall effect: Z = 2.11 (P	= 0.04)						
Test for overall effect: Z = 2.11 (P		21	Conf	rol			Favours [fluoxetine] Favours [control]
;	SSF		Cont		l Weight	Odds Ratio	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup	SSF				Weight		Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine	SSF Events	Total	Events	Total		Odds Ratio M-H. Fixed, 95% Cl	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020	SSF Events	Total	Events 6	Tota	15.1%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020	SSF Events 19 28	Total 642 750	Events 6 11	Tota 638 750	5 15.1% 27.3%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10] 2.61 [1.29, 5.27]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020	SSF Events	Total 642 750	Events 6	Total 638 750 1563	5 15.1% 27.3%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019	SSF Events 19 28	Total 642 750 1564	Events 6 11	Total 638 750 1563 2951	5 15.1% 27.3% 57.6%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2	SSF <u>Events</u> 19 28 45 92 45 (P = 0.62	Total 642 750 1564 2956 ?); I ² = (Events 6 11 23 40	Total 638 750 1563 2951	5 15.1% 27.3% 57.6%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events	SSF <u>Events</u> 19 28 45 92 45 (P = 0.62	Total 642 750 1564 2956 ?); I ² = (Events 6 11 23 40	Total 638 750 1563 2951	5 15.1% 27.3% 57.6%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2	SSF <u>Events</u> 19 28 45 92 45 (P = 0.62	Total 642 750 1564 2956 ?); I ² = (Events 6 11 23 40	Total 638 750 1563 2951	5 15.1% 27.3% 57.6%	Odds Ratio <u>M-H, Fixed, 95% Cl</u> 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F	SSF <u>Events</u> 19 28 45 92 45 (P = 0.62	Total 642 750 1564 2956 2); l ² = (1)	Events 6 11 23 40 0%	Total 638 750 1563 2951	5 15.1% 27.3% 57.6%	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram	SSF Events 19 28 45 92 (P = 0.62 2 < 0.0000	Total 642 750 1564 2956 2); l ² = (1)	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	57.6% 57.6% 100.0%	Odds Ratio M-H, Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018	SSF Events 19 28 45 92 (P = 0.62 2 < 0.0000	Total 642 750 1564 2956 2); l ² = (1) 319	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	 15.1% 27.3% 57.6% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018 Subtotal (95% CI)	SSF Events 19 28 45 92 92 92 92 92 92 92 92 92 92 92 92 92	Total 642 750 1564 2956 2); l ² = (1) 319	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	 15.1% 27.3% 57.6% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018 Subtotal (95% CI) Total events	SSF Events 19 28 45 92 (P = 0.62 2 < 0.0000 7 7 7	Total 642 750 1564 2956 2); l ² = (1) 319	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	 15.1% 27.3% 57.6% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018 Subtotal (95% CI) Total events Heterogeneity: Not applicable	SSF Events 19 28 45 92 (P = 0.62 2 < 0.0000 7 7 7	Total 642 750 1564 2956 2); l ² = (1) 319	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	 15.1% 27.3% 57.6% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018 Subtotal (95% CI) Total events Heterogeneity: Not applicable	SSF Events 19 28 45 92 (P = 0.62 2 < 0.0000 7 7 7	Total 642 750 1564 2956 2); l ² = (1) 319	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	 15.1% 27.3% 57.6% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio M-H, Fixed, 95% Cl
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018 Subtotal (95% CI) Total events Heterogeneity: Not applicable	SSF Events 19 28 45 92 (P = 0.62 2 < 0.0000 7 7 7	Total 642 750 1564 2956 2); l ² = (1) 319	Events 6 11 23 40 0%	Total 638 750 1563 2951 323	 15.1% 27.3% 57.6% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio M-H, Fixed, 95% Cl
Study or Subgroup 6.3.1 fluoxetine Affinity Trial Collaboration 2020 Effects Trial Collaboration 2020 Focus Trial Collaboration 2019 Subtotal (95% CI) Total events Heterogeneity: Chi ² = 0.95, df = 2 Test for overall effect: Z = 4.44 (F 6.3.2 citalopram Kraglund 2018 Subtotal (95% CI) Total events Heterogeneity: Not applicable	SSF Events 19 28 45 92 (P = 0.62 0 < 0.0000 7 7 7 2 = 0.07)	Total 642 750 1564 2956 2); l ² = (1) 319 319	Events 6 11 23 40 0% 1 1	Total 638 750 1563 2951 323 323	 15.1% 27.3% 57.6% 100.0% 100.0% 100.0% 	Odds Ratio M-H. Fixed, 95% Cl 3.21 [1.27, 8.10] 2.61 [1.29, 5.27] 1.98 [1.19, 3.29] 2.34 [1.61, 3.40] 7.22 [0.88, 59.06]	Favours [fluoxetine] Favours [control] Odds Ratio M-H, Fixed, 95% CI

included RCTs have good homogeneity, so the combined results are reliable.

Potential Biases in the Review Process

In the process of review, two authors conducted the review separately, and when the results were inconsistent, the decision was made after consultation with the third author, which was less likely to make mistakes than the repeated review by a single author twice. However, there might still be some limitations. On the one hand, only fluoxetine, citalopram, and escitalopram are included in our metaanalysis, so we can not draw conclusions about other SSRIs that are not included. On the other hand, we only include studies published in English, which might result in missing some high-quality, large-sample RCTs published in other languages.

Agreements and Disagreements With Other Studies or Reviews

Our meta-analysis focuses on the motor recovery after acute stroke in non-depressed patients treated with SSRIs, and the consistency and inconsistency with previously published studies are as follows.

Regarding efficacy, our results showed that fluoxetine and citalopram improved FMMS score but not NIHSS, BI, and mRS score, which is consistent with the results of

AEs	RCTs (N)	OR [95% CI]	Heterogeneity	Effect model	Overall effect (P-value)
Attempted or actual suicide	3	0.82 [0.23–2.84]	$P = 0.52, l^2 = 0\%$	Fixed	P = 0.75
Fall with injury	vith injury 2		$P = 0.08, I^2 = 66\%$	Random	P = 0.15
Upper gastrointestinal bleed	gastrointestinal bleed 3		$P = 0.98, I^2 = 0\%$	Fixed	P = 0.38
Haemorrhagic stroke	hagic stroke 4		$P = 0.47, I^2 = 0\%$	Fixed	P = 0.73
All bleeding events	eding events 4		$P = 0.84, I^2 = 0\%$	Fixed	P = 0.34
Acute coronary events	cute coronary events 4		$P = 0.79, I^2 = 0\%$	Fixed	P = 0.06
Ischaemic stroke	4	0.93 [0.69–1.25]	$P = 0.28, I^2 = 21\%$	Fixed	P = 0.64
All thrombotic events	3	0.76 [0.58–1.00]	$P = 0.42, I^2 = 0\%$	Fixed	P = 0.05
Diarrhea	4	1.83 [0.90–3.71]	$P = 0.48, I^2 = 0\%$	Fixed	P = 0.09
Any Stroke	3	0.93 [0.71–1.21]	$P = 0.24, I^2 = 30\%$	Fixed	P = 0.58
Insomnia	6	0.96 [0.60–1.52]	$P = 0.81, I^2 = 0\%$	Fixed	P = 0.86
Abnormal liver function	2	0.54 [0.25–1.17]	$P = 0.63, I^2 = 0\%$	Fixed	P = 0.12
Dizziness	ess 3		$P = 0.38, I^2 = 0\%$	Fixed	P = 0.87
Headache	2	4.23 [0.46–39.26]	$P = 0.84, I^2 = 0\%$	Fixed	P = 0.20
Sweating	3	5.29 [0.90–31.15]	$P = 0.91, I^2 = 0\%$	Fixed	P = 0.07
Increased appetite	2	3.90 [0.77–19.79]	$P = 0.88, I^2 = 0\%$	Fixed	P = 0.10
Palpitation	3	0.97 [0.13–6.99]	$P = 0.34, I^2 = 0\%$	Fixed	P = 0.97
Abdominal pain	2	1.73 [0.50–6.00]	$P = 0.49, I^2 = 0\%$	Fixed	P = 0.39
Death	8	0.99 [0.80–1.22]	$P = 0.58, I^2 = 0\%$	Fixed	P = 0.91
Drowsiness	3	1.55 [0.74–3.27]	$P = 0.94, I^2 = 0\%$	Fixed	P = 0.25
Fatigue	2	0.98 [0.37-2.60]	$P = 0.52, I^2 = 0\%$	Fixed	P = 0.97
Sexual Dysfunction	3	1.71 [0.73–4.03]	$P = 0.73, I^2 = 0\%$	Fixed	P = 0.22
Restlessness	2	3.00 [0.12-77.17]	-	Fixed	P = 0.51
Hyperglycaemia	3	0.73 [0.17–3.10]	$P = 0.02, I^2 = 83\%$	Random	P = 0.67
Symptomatic hypoglycaemia	2	1.78 [0.90–3.53]	-	Fixed	P = 0.10

AEs, adverse events; SSRIs, selective serotonin reuptake inhibitors; RCTs, randomized controlled trials; OR, odds ratios; CI, confidence intervals.


Zhou et al. (25), while Mead et al. (7) showed SSRIs improved dependence, disability, and neurological impairment, which is inconsistent with our results. However, due to the inclusion of patients with post-stroke depression in the study, the incomplete use of a matching placebo in the control group, and, most importantly, the high heterogeneity and methodological limitations between the studies, thus the results are less reliable. The results of subsequent Legg et al. (9) are basically consistent with ours, which only included low risk of bias RCTs, and concluded that SSRIs could not improve dependence, disability, and neurological impairment, but the number of included RCTs and the effect size is small.

Regarding AEs, we found that fluoxetine was associated with hyponatremia, seizure, and fracture, but Mead et al., Legg et al., and Jones et al. (7, 9, 26) found no significant difference in the incidence of seizure between the two groups. The reason why the results are inconsistent is that the studies included are different. Zhou et al. (25) showed that SSRIs increased the incidence of nausea and seizure, and decreased the incidence of psychiatric disorders. The findings of seizure are consistent with ours, but we found no evidence for nausea or psychiatric disorders. Jones et al. (26) showed that SSRIs could increase the risk of fracture and the studies included were the same as ours. But considering that fluoxetine and citalopram were involved, we made an analysis based on the type of drugs. Since there was only one study of citalopram, we could not conclude that citalopram increased the risk of fracture. Other AEs not associated with SSRIs, such as falls and recurrent stroke, are consistent with our study. Besides, the data for hyponatremia is not mentioned in these four studies.

CONCLUSIONS

Implications for Practice

Our meta-analysis can not provide sufficient evidence for the routine use of SSRIs in patients not clinically diagnosed with depression following acute stroke. Current results suggested that fluoxetine and citalopram could improve FMMS scores in patients with acute stroke, but NIHSS, BI, and mRS scores were not significantly improved, and data on the motor components of NIHSS scores were unavailable. The difference in the evaluation emphasis of each scale may be a factor for the difference in the results. In addition, patients with acute stroke accompanied by aphasia and cognitive impairment are also common in clinical work, and there is no relevant evidence for these patients. And that fluoxetine may increase the risk of hyponatremia, seizure, and fracture, so the prevention of these possible AEs should be worth our attention. Therefore, in clinical practice, it is necessary to



carefully evaluate and weigh the advantages and disadvantages before deciding whether to use SSRIs in combination with the actual situation of patients. If we finally decide to initiate an SSRI, we should consider targeted prevention of these AEs to maximize the benefits.

Implications for Research

Fluoxetine is the most commonly used drug in RCTs included in our meta-analysis, and it is also currently used in several

large-scale RCTs, so it could be the first choice for future studies. However, there is still a lack of data on whether other drugs other than fluoxetine improve motor recovery after acute stroke, thus we look forward to further large RCTs to supplement the existing evidence. Future studies should also focus on the occurrence of AEs and include patients with aphasia and cognitive impairment so that the results can be more applicable to clinical practice. We also look forward to future network meta-analyses to select the antidepressant with the best efficacy and tolerability when data are available.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/**Supplementary Material**, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

CWa and NS contributed conception and design of the study. YY and NS organized the database. CWe and NS performed the statistical analysis. CWa wrote the first draft of the manuscript.

REFERENCES

- George MG, Fischer L, Koroshetz W, Bushnell C, Frankel M, Foltz J, et al. CDC grand rounds: public health strategies to prevent and treat strokes. *MMWR Morb Mortal Wkly Rep.* (2017) 66:479–81. doi: 10.15585/mmwr.mm6618a5
- GBD 2015 Disease and Injury, Incidence, and Prevalence, Collaborators. Global, regional, national incidence. prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet.* (2016) 388:1545–602. doi: 10.1016/S0140-6736(16)31678-6
- GBD 2016 Stroke, Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* (2019) 18:439–58. doi: 10.1016/S1474-4422(19)30034-1
- Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol.* (2011) 10:123–30. doi: 10.1016/S1474-4422(10)70314-8
- FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. *Lancet.* (2019) 393:265–74. doi: 10.1016/S0140-6736(18)3 2823-X
- Affinity Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* (2020) 19:651–60. doi: 10.1016/S1474-4422(20)30207-6
- Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. *Cochrane Database Syst Rev.* (2012) 11:CD009286. doi: 10.1002/14651858.CD009286.pub2
- Effects Trial Collaboration. Safety and efficacy of fluoxetine on functional recovery after acute stroke (EFFECTS): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* (2020) 19:661–9. doi: 10.1016/S.1474-4422(20)30219-2
- Legg LA, Tilney R, Hsieh CF, Wu S, Lundstrom E, Rudberg AS, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. *Cochrane Database Syst Rev.* (2019) 2019:CD009286. doi: 10.1002/14651858.CD0092 86.pub3
- Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* (2009) 339:b2535. doi: 10.1136/bmj. b2535
- Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The cochrane collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* (2011) 343:d5928. doi: 10.1136/bmj. d5928

NS wrote sections of the manuscript. SG and CWe revised and proofread the manuscript. All authors contributed to the article and approved the submitted version.

ACKNOWLEDGMENTS

We would like to thank the authors of the original studies for their contributions.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur. 2021.749322/full#supplementary-material

- Gladstone DJ, Danells CJ, Black SE. The fugl-meyer assessment of motor recovery after stroke: a critical review of its measurement properties. *Neurorehabil Neural Repair.* (2002) 16:232–40. doi: 10.1177/154596802401105171
- Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* (2014) 14:135. doi: 10.1186/1471-2288-14-135
- Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res.* (2018) 27:1785–805. doi: 10.1177/09622802166 69183
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BM J. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557
- Bighelli I, Castellazzi M, Cipriani A, Girlanda F, Guaiana G, Koesters M, et al. Antidepressants versus placebo for panic disorder in adults. *Cochrane Database Syst Rev.* (2018) 4:CD010676. doi: 10.1002/14651858.CD010676.pub2
- Shi J, Wu X, Chen Y. Study on dalfampridine in the treatment of multiple sclerosis mobility disability: a meta-analysis. *PLoS ONE*. (2019) 14:e0222288. doi: 10.1371/journal.pone.0222288
- Wang X, Dai G, Li M, Jia W, Guo Z, Lu J. Prevalence of human alveolar echinococcosis in China: a systematic review and metaanalysis. *BMC Public Health.* (2020) 20:1105. doi: 10.1186/s12889-020-0 8989-8
- Nawijn F, Smeeing DPJ, Houwert RM, Leenen LPH, Hietbrink F. Time is of the essence when treating necrotizing soft tissue infections: a systematic review and meta-analysis. World J Emerg Surg. (2020) 15:4. doi: 10.1186/s13017-019-0286-6
- Asadollahi M, Ramezani M, Khanmoradi Z, Karimialavijeh E. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. *Clin Rehabil.* (2018) 32:1069–75. doi: 10.1177/0269215518777791
- Kraglund KL, Mortensen JK, Damsbo AG, Modrau B, Simonsen SA, Iversen HK, et al. Neuroregeneration and vascular protection by citalopram in acute ischemic stroke (TALOS). *Stroke.* (2018) 49:2568–76. doi: 10.1161/STROKEAHA.117.020067
- 22. Kim JS, Lee EJ, Chang DI, Park JH, Ahn SH, Cha JK, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. *Lancet Psychiatry.* (2017) 4:33–41. doi: 10.1016/S2215-0366(16)30417-5
- Marquez-Romero JM, Reyes-Martinez M, Huerta-Franco MR, Ruiz-Franco A, Silos H, Arauz A. Fluoxetine for motor recovery after acute intracerebral hemorrhage, the FMRICH trial. *Clin Neurol Neurosurg.* (2020) 190:105656. doi: 10.1016/j.clineuro.2019.105656
- 24. Savadi Oskouie D, Sharifipour E, Sadeghi Bazargani H, Hashemilar M, Nikanfar M, Ghazanfari Amlashi S, et al. Efficacy of citalopram on acute

ischemic stroke outcome: a randomized clinical trial. Neurorehabil Neural Repair. (2017) 31:638-47. doi: 10.1177/1545968317704902

- Zhou S, Liu S, Liu X, Zhuang W. Selective serotonin reuptake inhibitors for functional independence and depression prevention in early stage of post-stroke: a meta-analysis. *Medicine*. (2020) 99:e19062. doi: 10.1097/MD.000000000019062
- Jones JS, Kimata R, Almeida OP, Hankey GJ. Risk of fractures in stroke patients treated with a selective serotonin reuptake inhibitor: a systematic review and meta-analysis. *Stroke.* (2021) 52:2802–8. doi: 10.1161/STROKEAHA.120.032973

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Su, Wen, Guo, Yu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.